Home Daily Intelligence Tracker
    • Plans Blog Contact
    ResMed Inc logo
    RMD

    ResMed Inc

    MaveScore 47 Low model confidence
    Last Price US$204.59 As of Jul 10, 2026
    DCF Fair Price US$193.45 Research estimate · Jul 10, 2026 -7.4% vs price
    Market Cap US$29.7b Company size context
    7D Performance -2.72% Past 7 days
    1Y Performance -20.98% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 47 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    24/35 Mixed

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    15/25 Mixed

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    4/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    2/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    2/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Favors positive earnings, positive cash flow, and lower multiples.
    • Highlights research candidates with supportive 3-month and 6-month price regimes.
    • Rewards less dilutive share behavior and enough size for liquid research coverage.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    ResMed Inc Overview

    Industry: Medical Instruments & Supplies

    Sector: Healthcare

    ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respirat Read More

    ResMed Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    ResMed Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 30, 2026

    Quarterly result summary

    Revenue was $1.4B (+11% YoY); EPS was $2.74 (reported).

    Revenue $1.4B +11% YoY
    EPS $2.74 reported
    Operating income $499.8M +17% YoY
    Net income $417M reported

    What changed

    • Revenue +11% YoY to $1.4B; EPS reported to $2.74.
    • Operating income +17% YoY to $499.8M.

    Capital return

    Dividend declared at $0.60/share.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K Jul 07, 2026 SEC filing EX-99.1 Jul 07, 2026 SEC filing 10-Q May 01, 2026 SEC filing 8-K Apr 30, 2026 SEC filing 10-Q Jan 30, 2026 Earnings release Earnings release Jan 29, 2026 SEC filing 8-K Jan 29, 2026 SEC filing 10-Q Oct 31, 2025 SEC filing 8-K Oct 30, 2025 Earnings release Earnings release Oct 30, 2025 SEC filing 10-K Aug 08, 2025

    Recent News



    Mackenzie Financial Corp Sells 7,569 Shares of ResMed Inc. $RMD
    28 minutes ago
    Russell Investments Group Ltd. Buys 8,601 Shares of ResMed Inc. $RMD
    1 hour ago
    Hsbc Holdings PLC Boosts Stake in ResMed Inc. $RMD
    1 hour ago

    Earnings Per Share

    Score 4.00/5
    ResMed Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Return on Equity

    Score 4.56/5
    ResMed Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ResMed Inc RMD US$29.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 4.88/5
    ResMed Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    ResMed Inc RMD US$29.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Instruments & Supplies industry , West Pharmaceutical Services Inc , Hologic Inc , Haemonetics are companies with high ratings.

    Leverage

    Score 2.43/5
    ResMed Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    ResMed Inc RMD US$29.7b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    ResMed Inc logo

    ResMed Inc

    US$204.59

    US$193.45

    -7.4% vs price

    US$29.7b

    -2.72%

    -20.98%